logo
Plus   Neg
Share
Email

Gilead & Vir Announce Collaboration To Find Cure For Hepatitis B Virus - Quick Facts

Gilead Sciences, Inc. (GILD) and Vir Biotechnology, Inc. (VIR) have entered into a clinical collaboration to evaluate therapeutic combination strategies aimed at developing a functional cure for chronic hepatitis B virus. The companies plan to initiate a phase 2 trial evaluating combination therapy for both treatment-experienced and treatment-naïve people living with hepatitis B virus.

The multi-arm trial will evaluate different combinations of selgantolimod, Gilead's investigational TLR-8 agonist; VIR-2218, Vir's investigational small interfering ribonucleic acid. The companies will discuss the potential path forward for any future combination studies based on the outcome of the phase 2 trial.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pfizer has uncovered the counterfeit versions of its Covid-19 vaccine in Mexico and Poland, according to a Wall Street Journal report. The vaccine was developed in partnership with Germany's BioNTech SE. Though there have been several reports of counterfeit versions of the Covid-19 vaccine, this seems to be the first confirmed instance. American Airlines is planning to resume hiring pilots this year to meet a rebound in travel demand in the summer season, reports said citing a company memo. The airline is expected to add 300 pilots by the end of the year and double that in 2022. Verizon Communications Inc. (VZ) reported a profit for the first-quarter that increased 25.4 percent from last year, reflecting growth in wireless service revenue, wireless equipment revenue and total Fios Internet net additions. Quarterly operating revenues rose 4.0 percent from the prior year.
Follow RTT